These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

890 related items for PubMed ID: 25226868

  • 1. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 2. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [Abstract] [Full Text] [Related]

  • 3. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 5. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ.
    Mult Scler; 2014 Sep; 20(10):1381-90. PubMed ID: 24852928
    [Abstract] [Full Text] [Related]

  • 6. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 7. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [Abstract] [Full Text] [Related]

  • 9. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M.
    Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
    [Abstract] [Full Text] [Related]

  • 10. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013 May; 129(5):548-9. PubMed ID: 23520898
    [Abstract] [Full Text] [Related]

  • 11. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 12. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
    Hoepner R, Havla J, Eienbröker C, Tackenberg B, Hellwig K, Meinl I, Hohlfeld R, Gold R, Kümpfel T, Kleiter I.
    Mult Scler; 2014 Nov 04; 20(13):1714-20. PubMed ID: 24842961
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
    Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T.
    Arch Neurol; 2012 Feb 04; 69(2):262-4. PubMed ID: 22332194
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P.
    Mult Scler; 2012 Nov 04; 18(11):1640-3. PubMed ID: 23100526
    [Abstract] [Full Text] [Related]

  • 17. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
    Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.
    Clin Neurol Neurosurg; 2014 Apr 04; 119():17-20. PubMed ID: 24635919
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.
    Acta Neurol Scand; 2012 Nov 04; 126(5):306-14. PubMed ID: 22107083
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.
    Eur J Neurol; 2010 Jan 04; 17(1):31-7. PubMed ID: 19614963
    [Abstract] [Full Text] [Related]

  • 20. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 04; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.